Amylases
Amylases are crucial enzymes which hydrolyze internal glycosidic linkages in starch and produce as primary products dextrins and oligosaccharides. Amylases are classified into α-amylase, β-amylase, and glucoamylase based on their three-dimensional structures, reaction mechanisms, and amino acid sequences. Amylases have innumerable applications in clinical, medical, and analytical chemistries as well as in food, detergent, textile, brewing, and distilling industries.
All Product Categories
-
Amylases Related Products (105)
Related Products (105)
-
Quinoline-2-carboxylic acid-d6
0 ImagesCat. No.: HY-W002011SCAS No.: 1219802-18-2Quinoline-2-carboxylic acid-d6 is the deuterium labeled Quinoline-2-carboxylic acid (HY-W002011). Quinoline-2-carboxylic acid exhibits antidiabetic activity. Quinoline-2-carboxylic acid can be used as drug intermediate for synthesis of various active compounds.
-
α-Amylase/α-Glucosidase-IN-18
0 ImagesCat. No.: HY-168961α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for α-Amylase and α-Glucosidase with IC50 of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus.
-
Antidiabetic agent 2
0 ImagesCat. No.: HY-155961CAS No.: 3052242-32-4Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels.
-
Dehydrocholic acid (Standard)
0 ImagesDehydrocholic acid (Dehydrocholate) (Standard) is the analytical standard of Dehydrocholic acid (HY-B1393). This product is intended for research and analytical applications. Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice.
-
(±)7(8)-DiHDTE
0 ImagesCat. No.: HY-172832(±)7(8)-DiHDTE is a metabolite of Docosapentaenoic acid (22n-3) (HY-113159). Docosapentaenoic acid (22n-3) is a component of phospholipids. Docosapentaenoic acid 22n-3 has inhibitory activity against α-amylase and α-glucosidase with IC50s of 17 and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 increases cell vitality. Docosapentaenoic acid 22n-3 has a weak anti-inflammatory effect.
-
α-Amylase/α-Glucosidase-IN-23
0 ImagesCat. No.: HY-179141CAS No.: 2093387-94-9α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a α-Amylase/α-Glucosidase inhibitor with IC50 values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia.
-
8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside
0 ImagesCat. No.: HY-N9916CAS No.: 925701-05-98,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) is natural product that can be isolated from Bidens bipinnata. 8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside shows 22% inhibition against α-amylase at 0.556 mg/mL.
-
α-Amylase/α-Glucosidase-IN-12
0 ImagesCat. No.: HY-163439α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC50 of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research.
-
Luteolin 4'-O-β-D-glucuronopyranoside
0 ImagesCat. No.: HY-N17674CAS No.: 53527-43-8Luteolin 4'-O-β-D-glucuronopyranoside is a flavonoid glycoside. Luteolin 4'-O-β-D-glucuronopyranoside can be isolated from the aerial parts of C. rotundus L.. Luteolin 4'-O-β-D-glucuronopyranoside inhibits α-amylase. Luteolin 4'-O-β-D-glucuronopyranoside shows antioxidant activity. Luteolin 4'-O-β-D-glucuronopyranoside can be used in research on diabetes.
-
α-Amylase/α-Glucosidase-IN-17
0 ImagesCat. No.: HY-172211α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects.
-
α-Amylase-IN-5
0 ImagesCat. No.: HY-157537CAS No.: 2996821-90-8α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC50 of 18.8 mM.
-
α-Amylase/α-Glucosidase-IN-20
0 ImagesCat. No.: HY-174319α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of α-Amylase and α-Glucosidase with IC50s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research.
-
α-Amylase-IN-8
0 ImagesCat. No.: HY-161944CAS No.: 1503788-07-5α-Amylase-IN-8 (compound 44) is an α-amylase inhibitor (IC50=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes.
-
Carveol (Standard)
0 ImagesCat. No.: HY-W017370RCAS No.: 99-48-9Carveol (Standard) is the analytical standard of Carveol. This product is intended for research and analytical applications. Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke.
-
3,5,6,7,8,4'-Hexamethoxyflavone
0 Images3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM.
-
α-Amylase/α-Glucosidase-IN-24
0 ImagesCat. No.: HY-184380CAS No.: 450380-22-0α-Amylase/α-Glucosidase-IN-24 is a dual inhibitor of α-amylase and α-glucosidase, with IC50 values of 40.18 μg/mL and 31.80 μg/mL, respectively. α-Amylase/α-Glucosidase-IN-24 exhibits weak anti-inflammatory and antioxidant activities, as well as moderate antibacterial activity. α-Amylase/α-Glucosidase-IN-24 can be used for the research of type 2 diabetes.
-
Stigmast-5-en-3-ol
0 ImagesStigmast-5-en-3-ol induces cancer cell apoptosis and inhibits proliferation by increasing the production of Bax, Caspase-9, p53, and PARP cleavage and reducing Bcl-xl expression. Stigmast-5-en-3-ol exhibits potent inhibitory activity against glucoamylase and α-amylase and possesses high antioxidant activity. Stigmast-5-en-3-ol can be used in the research of diseases such as leukemia, breast cancer, type 2 diabetes, and obesity.
-
MAO-B-IN-46
0 ImagesCat. No.: HY-W207699CAS No.: 27052-20-6MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance.
